Centessa Pharmaceuticals plc (CNTA)

Jun 24, 2026 - CNTA was delisted (reason: acquired by LLY)

40.50

+0.32 (0.80%)

Inactive · Last trade price on Jun 23, 2026

Centessa Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '20 Dec 31, 2020
Net Income	-250.64	-197.53	-235.76	-151.09	-216.21	-10.66
Depreciation & Amortization	0.94	0.92	0.94	0.81	0.13	-
Stock-Based Compensation	33.64	30.96	33.55	29.39	24.97	0.34
Other Adjustments	4.62	1.86	37.05	-20.63	-6.78	0.24
Changes in Accounts Payable	5.41	0.05	-4.59	-2.72	6.35	-0.05
Changes in Accrued Expenses	5.32	-15.22	22.77	-0.8	6.26	0.65
Changes in Other Operating Activities	-7.99	-14.86	3.98	-15.31	-15.27	-1.15
Operating Cash Flow	-208.8	-193.82	-142.06	-160.34	-200.55	-10.63
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '20 Dec 31, 2020
Capital Expenditures	-0.31	-0.37	-0.03	-0.17	-1.14	-
Purchases of Investments	-517.82	-739.76	-140.53	-264.91	-	-
Proceeds from Sale of Investments	364.76	321.6	171.83	138.08	-	-
Other Investing Activities	-	-	-	-	0.21	-
Investing Cash Flow	-153.44	-418.53	31.27	-127	-0.93	-

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '20 Dec 31, 2020
Long-Term Debt Issued	-	-	109.34	-	-	1.36
Long-Term Debt Repaid	-	-	-110.1	-	-	-
Net Long-Term Debt Issued (Repaid)	-	-	-0.76	-	-	1.36
Issuance of Common Stock	53.72	296.72	370.83	21.12	0.72	0
Repurchase of Common Stock	-4.06	-4.79	-5.32	-	-	-
Net Common Stock Issued (Repurchased)	49.67	291.93	365.51	21.12	0.72	0
Other Financing Activities	4.39	-0.4	-	-	-0.26	-
Financing Cash Flow	318.91	291.53	364.75	21.12	0.46	1.36

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '20 Dec 31, 2020
Foreign Exchange Rate Adjustments	1.25	-0.45	1.23	0.62	-0.42	-0.08
Net Cash Flow	-42.07	-321.27	255.19	-265.61	-201.44	-9.34

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '20 Dec 31, 2020
Free Cash Flow	-209.1	-194.19	-142.09	-160.51	-201.68	-10.63
Free Cash Flow Growth	-	-	-	-	-	-
FCF Margin	-	-1294.59%	-	-2342.20%	-	-
Free Cash Flow Per Share	-1.48	-1.43	-1.24	-1.67	-2.16	-2.71
Levered Free Cash Flow	-247.26	-227.01	-213.45	-169.27	-219.87	-9.85
Unlevered Free Cash Flow	-254.62	-239.1	-180.44	-165.11	-215.2	-10.99

SEC Filings: 10-K · 10-Q